发散的婴儿肝脏血管瘤成功地用口服普拉诺洛尔治疗:一个病例报告和文献综述
Zengyan Li1, Zhiming Wu2, Youhong Dong1
1Department of Oncology, Xiangyang No. 1 People's Hospital, Hubei University of Medicine, Xiangyang, China.
Frontiers in oncology
|February 13, 2024
概括
扩散性婴儿肝血管瘤 (DIHH) 是一种罕见的疾病. 普罗普拉诺洛尔单一疗法提供了一种安全有效的治疗方法,导致幼儿的完全缓解.
科学领域:
- 儿科肝病学 儿科肝病学
- 血管异常 血管异常
- 药物治疗 药物治疗
背景情况:
- 扩散性婴儿肝血管瘤 (DIHH) 是婴儿肝血管瘤 (IHH) 的一种罕见的,激进的形式.
- DIHH呈现为广泛的肝脏内病变,可能导致显著的发病率.
- 目前尚缺少DIHH的标准化治疗方案.
研究的目的:
- 报告一个DIHH病例成功地用普罗普兰诺洛单一治疗.
- 评估用于DIHH的propranolol的疗效和安全性.
主要方法:
- 一个患有DIHH的2个月大的婴儿接受了口服普罗普兰诺洛的治疗.
- 剂量从每天0.5 mg/kg升至每天2 mg/kg.
- 通过成像和临床评估监测治疗反应.
主要成果:
- 婴儿在一年的propranolol治疗后实现了DIHH的完全缓解.
- 在治疗期间没有观察到任何显著的不良反应.
- 图像检测证实肝脏内病变的几乎完全回归.
结论:
- 普罗普拉诺洛尔单一治疗是一种安全有效的第一线治疗DIHH.
- 使用普拉诺洛尔的及时干预可以防止与DIHH相关的危及生命的并发症.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
181
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
181
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
803
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
803
Esophageal Varices-II: Clinical Features and Management
67
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
67
Antihypertensive Drugs: Vasodilators
524
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
524
Drug Delivery: Enteral Route
451
The enteral drug administration involves three primary routes: oral, sublingual, and buccal. Oral ingestion is the most prevalent, safe, economical, and convenient method for drug administration. However, it has certain drawbacks, including limited absorption due to the drug's low water solubility or poor membrane permeability, possible emesis from GI mucosa irritation, destruction of drugs by digestive enzymes or low gastric pH, and irregular absorption along with food or other drugs.
451
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
166
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
166


